Sun’s Tildrakizumab Deal: A Calculated Bet?
This article was originally published in PharmAsia News
Executive Summary
If approved, tildrakizumab, licensed in globally by Sun Pharma but developed by Merck, will be pitted against established competitors in a crowded market of advanced biologics for plaque psoriasis. But experts believe several advantages can help the top Indian generic firm leap into the wide world of dermatology and anti-inflammatory compounds.